Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Saniona ABCHIX:SANIOS 65 Return-on-Tangible-Asset is -27.91% as of Mar. 2026. GuruFocus rates CHIX:SANIOS with a GF Score™ of 65/100 and a GF Value™ of kr25.78 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Saniona AB ranks better than 97.88% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Saniona AB's annualizedNet Income for the quarter that ended in Mar. 2026 was kr-184.6 Mil. Saniona AB's average total tangible assets for the quarter that ended in Mar. 2026 was kr661.5 Mil. Therefore, Saniona AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -27.91%.
The historical rank and industry rank for Saniona AB's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:SANIOs'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -92.95 Med: -67.06 Max: 95.75
Current: 38.89
During the past 13 years, Saniona AB's highest Return-on-Tangible-Asset was 95.75%. The lowest was -92.95%. And the median was -67.06%.
CHIX:SANIOs's Return-on-Tangible-Asset is ranked better than 97.88% of 1416
companies
in the Biotechnology industry
Industry Median: -35.915
vs CHIX:SANIOs: 38.89
Saniona AB (CHIX:SANIOs) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Saniona AB Return-on-Tangible-Asset Related Terms
Saniona AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Saniona AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SANIOS vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Saniona AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Saniona AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -27.91% mean?
Saniona AB (CHIX:SANIOS) has a Return-on-Tangible-Asset of -27.91% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #30 out of 1416 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Saniona AB's Return-on-Tangible-Asset too high?
Saniona AB's current Return-on-Tangible-Asset is -27.91%. Based on the distribution chart, Saniona AB ranks #30 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Saniona AB has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #30 out of 1416 companies for Return-on-Tangible-Asset. This places Saniona AB in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Saniona AB and its competitors. Saniona AB's current Return-on-Tangible-Asset is -27.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr25.78, compared to a current price of kr12.75 — trading 50.5% below its estimated fair value. The current Return-on-Tangible-Asset is -27.91%. Saniona AB's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current Return-on-Tangible-Asset is -27.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr12.75 is trading 50.5% below its estimated GF Value™ of kr25.78.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for CHIX:SANIOS:
Return-on-Tangible-Asset: -27.91%
GF Value™: kr25.78 vs. price of kr12.75 (50.5% below fair value)
No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
65GF Score
Get the complete analysis for CHIX:SANIOS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SANIOS has been successfully added to your 
